Tokenization and funding for science and innovation
The global market for scientific assets.
We connect capital with validated scientific assets for investment, licensing, tokenization and strategic partnerships.
Governed by scientific committee · KYC / AML · Auditable tokenisation ledger
Live platform indicators
How AXIOM works
Science → due diligence → structuring → funding → licensing.
Every asset moves through the same disciplined sequence — from bench research to global scale — with governance, valuation and documentation at each gate.
Research
Origination from universities, ICTs and corporate labs, screened against market pull.
Prototype
Proof-of-concept engineering with defined success criteria and a costed development plan.
Scientific validation
Independent replication, GLP studies and peer-reviewed publication of core claims.
IP protection
Freedom-to-operate analysis, priority filings and PCT strategy per target market.
Valuation
Risk-adjusted NPV and comparables, audited assumptions, sensitivity ranges disclosed.
Capital raising
Structured rounds with VC, family offices, ESG funds and Lei do Bem corporate sponsorship.
Licensing
Territory and field-of-use agreements with milestone architecture and audit rights.
Royalties
Transparent royalty accounting, quarterly reporting and secondary participation options.
Global scale
International partners, regulatory expansion and manufacturing transfer at scale.
Mandate
Science becomes an investable asset class when it is documented, governed and priced.
Institutional diligence
Every asset enters through a scientific committee, a documented evidence base and an independent valuation opinion before it is listed.
Structured capital
Licensing, royalties, equity, tokenized participation and Lei do Bem incentives are combined into a single, auditable capital structure.
Measured outcome
Scientific milestones, regulatory gates and impact indicators are reported continuously to investors, industry and institutions.
Scientific assets
Validated science, structured for capital.
Filter the asset book by development stage and read the live dossier — valuation, capital requirement, market size and committee scores.
NXS-01
Oncolytic Peptide Platform
Biopharmaceuticals
A synthetic peptide platform that selectively lyses solid-tumor membranes while sparing healthy tissue, validated in three orthotopic models with a 68% tumor-volume reduction.
Valuation
US$ 96M
Capital need
US$ 24M
Market
US$ 248B
Intelligence & governance
One panel for evidence, controls and exposure.
Scientific validation
80
Committee-reviewed evidence base
Regulatory readiness
70
ANVISA / FDA / EMA pathways mapped
ESG alignment
82
Mapped to UN SDG targets
Expansion capacity
82
Industrial and cross-border scalability
Network
Industry, institutions and capital in one network.
Institutional infrastructure
The layers that make science investable.
Start a conversation under NDA.
Tell us whether you represent a company, an investor, a family office, an ICT, a university or a government body — the flow adapts to your mandate.